RASSF1 and lung cancer: Furthermore, Huiling et al. demonstrated that a combined analysis of RASSF1A and SHOX2 methylation using BALF samples collected from patients with lung cancer and benign lung diseases showed 88.24% sensitivity and 81.25% specificity [20].